Autopsy report · NCT04363203

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

“concerns related to study drug”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 300 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 3

Sponsor

Salomeh Keyhani MD

Sponsor type

US federal agency

Conditions

SARS-CoV-2; COVID-19

Interventions

Hydroxychloroquine; Azithromycin; Placebo oral tablet

Participants

300 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
  “study drug unavailable” (75% match in meaning)
• Study of Vioxx and Radiation Therapy for Brainstem Glioma
  “Unavailability of study drug.” (74% match in meaning)
• Topical Garlic Concentrate for Alopecia Areata in Children
  “Lack of efficacy of the study medication” (72% match in meaning)
• EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
  “Study drug supply issue” (70% match in meaning)
• Pre-Prostatectomy Celecoxib or Placebo
  “Drug safety concerns” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.